ReviewJournal of fungi (Basel, Switzerland)2020
Updated EUCAST Clinical Breakpoints against
Review in Journal of fungi (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 32 citations in OpenAlex.
- Functional characterization of SHC-like triterpene cyclase genes in azole response and virulence-related traits ofVirulence · 2026Article
- Prevalence ofJournal of fungi (Basel, Switzerland) · 2026Article
- Laboratory Diagnostics of Aspergillosis: Present State and Future Directions.Journal of fungi (Basel, Switzerland) · 2026Review
- Nitroxoline exerts potent anti-Antimicrobial agents and chemotherapy · 2026Article
- Invasive aspergillosis in lung and heart transplant recipients.JHLT open · 2026Article
- A One Health Perspective onJournal of fungi (Basel, Switzerland) · 2026Article
- Deep Fungal Infection of the Skin with Two Rare Fungi in a Dog Being Treated with Immunosuppressant Therapy: A Case Report.Veterinary sciences · 2025Article
- An Integrated Analysis Approach to Unravel theJournal of fungi (Basel, Switzerland) · 2025Article
- Azole drugs have differential efficacy in varied models of immunosuppression in larval zebrafish hosts.Future microbiology · 2025Article
- Doubling of triazole resistance rates in invasive aspergillosis over a 10-year period, Belgium, 1 April 2022 to 31 March 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Occurrence of Pathogenic and Allergenic Molds in the Outdoor and Indoor Environment of a Major Hospital and Molecular Epidemiology ofJournal of fungi (Basel, Switzerland) · 2025Article
- Boosting knowledge on occupational exposure to microbial contamination in Portuguese carpentries.Frontiers in public health · 2025Article
- Article
- Assessment of the microbial contamination in "Do It Yourself" (DIY) stores - a holistic approach to protect workers' and consumers' health.Frontiers in public health · 2024Article
- Genomic Epidemiology Identifies Azole Resistance Due to TRJournal of fungi (Basel, Switzerland) · 2023Article
- Potential Implication of Azole Persistence in the Treatment Failure of Two Haematological Patients Infected withJournal of fungi (Basel, Switzerland) · 2023Article
- Field-Crop Soils in Eastern France: Coldspots of Azole-ResistantJournal of fungi (Basel, Switzerland) · 2023Article
- Molecular epidemiology and antifungal susceptibilities of Aspergillus species isolated from patients with invasive aspergillosis.Revista da Associacao Medica Brasileira (1992) · 2023Article
- Article
- Azole Resistance andJournal of fungi (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Azole resistance poses a problem for the management of patients with invasive aspergillosis. Former species are in fact groups of closely related species (or complexes); cryptic species frequently show high antifungal resistance. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) EUCAST Definitive Document (E.Def) 9.3.2 includes guidelines for antifungal susceptibility testing on
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.